NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics's NTLA short percent of float has risen 11.06% since its last report. The company recently reported ...

Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.01 which represents a decrease of $-0.54 or -5.12% from the prior close of $10.55. The stock opened at $10.64 and touched a ...

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.99 which represents a decrease of $-0.30 or -2.66% from the prior close of $11.29. The stock opened at $11.25 and touched a ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.